20 C
Guwahati
Monday, April 12, 2021
More

    Glenmark Gets Approval For Favipiravir As COVID-19 Treatment

    The drug will be available as a prescription-based medication for around Rs 103 per tablet, with recommended doses up to day 14

    Guwahati: Glenmark Pharmaceuticals became India’s first pharmaceutical company to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19

    The pharmaceutical company based in Mumbai received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) on Friday.

     Glenmark will market the antiviral under the brand name FabiFlu.  

    FabiFlu is the first oral Favipiravir-approved medication for Covid-19, the company said in a statement. “The approval comes at a time when cases in India are spiraling like never before, putting a tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.

    The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure and offer patients in India a much needed and timely therapy option, he added.

    FabiFlu has demonstrated an encouraging response in mild to moderate Covid-19 patients during clinical trials.

    Moreover, it is orally administered, and so it serves as a more convenient treatment option over other intravenously administered medications, he noted.

    Saldanha said that Glenmark would work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country.

    The drug will be available as a prescription-based medication for around Rs 103 per tablet, with recommended doses up to day 14.

    The company claimed that Favipiravir could be used for coronavirus patients with co-morbid conditions such as diabetes and heart disease with mild to moderate Covid-19 symptoms.

    It offers rapid reduction in viral load within four days and provides faster symptomatic and radiological improvement, the drug maker added.                                                                                              

    Favipiravir has shown clinical improvement of up to 88 per cent in mild to moderate Covid-19 cases, it said.

    The drug firm had successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu through its in-house R&D team.

    According to Union Health Ministry, India on Saturday saw another record spike of 14,516 new Covid-19 cases in a single day, pushing the tally to 3, 95, 048, while the death toll rose to 12,948 with 375 new fatalities till filling of this report.

    Published:

    Follow TIME8.IN on TWITTER, INSTAGRAM, FACEBOOK and on YOUTUBE to stay in the know with what’s happening in the world around you – in real time

    First published

    TRENDING

    Jorhat Admin enforces section 144 CrPC amid surge in COVID-19 cases

    Six new people were tested positive to COVID-19 in Jorhat on Monday

    Assam: Writer Sikha Sarma receives rape threat in Facebook

    Rongmon Nath, a student of Gauhati University, made derogatory remarks against Sikha Sarma in a Facebook post.

    Dima Hasao: 5 polling officials suspended after EVM raised 181 votes against 90 voters

    A total of 171 votes were raised in an electronic voting machine (EVM) against 90 voters in Dima Hasao’s 16 Haflong (ST) LA constituency.

    BREAKING: ULFA (I) warns of ‘Action’ against Tata’s Amalgamated Plantation in Assam

    The outfit said that the company's head office was outside Assam where no indigenous personnel from Assam were in employment

    Assam Phase III Polls: Fate of 337 candidates in fray including 25 women

    Election Commission of India is ready to conduct polling at 11,401 centers

    Assam Polls: Police raid at Pramila Rani Brahma’s residence over alleged poll misconduct

    Pramila Rani Brahma and her party members misbehaved with us: SP Kokrajhar